A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

57

Enrollment

NETWORK

Sponsor class

Conditions

Low Grade Glioma (LGG) of Brain With BRAF Aberration
High Grade Glioma (HGG) of the Brain With BRAF Aberration
Low Grade Glioma of Brain With Neurofibromatosis Type 1

Interventions

DRUG: Dabrafenib
DRUG: Trametinib
DRUG: Hydroxychloroquine

Sponsor

Pediatric Brain Tumor Consortium

Collaborators

[object Object]
[object Object]